MedDataX Logo

Pregnancy Rates in IVF After Ovulation Triggering With Recombinant or Urinary Human Chorionic Gonadotrophin (HCG)

NCT ID: NCT00954265

Last Updated: 2009-12-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

130 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-08-31

Study Completion Date

2010-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To access whether the ovulation triggering with rec-HCG instead urinary-HCG has any impact on the blastulation rate and pregnancy rate of patients undergoing IVF treatment

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Embryonic Development Pregnancy VEGF

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

pregnancy occurence OHSS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Urinary-HCG group

These patients received u-HCG for ovulation triggering during ovarian stimulation for IVF

Group Type ACTIVE_COMPARATOR

10000 IU urinary HCG

Intervention Type DRUG

ovulation triggering

Recombinant HCG group

These patients received rec-HCG for ovulation triggering during ovarian stimulation for IVF

Group Type EXPERIMENTAL

250 mcg recombinant HCG

Intervention Type DRUG

ovulation triggering

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

10000 IU urinary HCG

ovulation triggering

Intervention Type DRUG

250 mcg recombinant HCG

ovulation triggering

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* FSH\<12,
* normal sperm,less than 36y,
* single blastocyst transfer

Exclusion Criteria

* endometriosis stage 3\&4,
* pco
Minimum Eligible Age

20 Years

Maximum Eligible Age

36 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Merck Serono International SA

INDUSTRY

Sponsor Role collaborator

Universitair Ziekenhuis Brussel

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Centre for Reproductive Medicine

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Paul Devroey, Professor

Role: STUDY_DIRECTOR

Professor or OB-GYN

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre for Reproductive Medicine, UZ Brussel

Brussels, Jette, Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

rec-HCG 002

Identifier Type: -

Identifier Source: org_study_id